Guide
Dental practice valuation: 2026 multiples, adjustments, and what changed since the DSO rollup peak
The multiples compressed through 2025. Here is where the market sits now and how to think about your own practice inside the new numbers.
The market for dental practices in 2026 is not the market of 2022. Capital is more expensive, several large DSOs are digesting acquisitions that did not perform on plan, and the easy money arbitrage of the rollup years has largely closed. Multiples compressed, and the shape of a fair offer changed.
This guide is a current snapshot of what the multiples actually look like, what adjustments buyers are making, and where your specific practice probably fits.
2026 EBITDA multiples by practice size
| Practice size | EBITDA multiple range | Notes |
|---|---|---|
| Solo GP, $800K–$1.2M revenue | 3.5x – 5.0x | Below scale threshold for most institutional buyers. Private-to-private sales or associate transitions typically yield better outcomes. |
| Solo GP, $1.2M–$2M revenue | 5.0x – 6.5x | Sweet spot for middle-market DSOs. Consistent demand. |
| Multi-doctor, $2M–$4M revenue | 6.0x – 8.0x | Scale premium. Multiple doctors reduce key-person operational risk. |
| Multi-location group, $4M+ | 7.0x – 9.5x | Platform premium if operations are genuinely integrated. Lower end if locations operate as siloes. |
| Specialty (endo, OS, perio, ortho) | 6.5x – 9.0x | Held up better than GP through the 2024–25 compression. |
These are ranges, not promises. Your specific practice lands somewhere inside the range based on the adjustments below.
The adjustments that move your multiple
Payer mix
Single biggest variable after practice size. A fee-for-service practice and a Medicaid-heavy practice with identical revenue are not worth the same, because they are not the same practice to a buyer.
- 60 percent or more fee-for-service: full multiple or above. Buyers pay premium for FFS because reimbursement is predictable and margin per chair is higher.
- 60–90 percent PPO: multiple holds, with adjustments for specific PPO concentration. One PPO at 40 percent of production is a risk factor. Three PPOs each under 20 percent is not.
- 50 percent or more Medicaid: multiple compresses 15–25 percent. Buyer universe narrows to operators who specialize in Medicaid-heavy models (Sonrava, a handful of regional operators). Fewer bidders means less competitive pressure on price.
Hygiene health
Hygiene is the department where a buyer can most easily see whether the practice is being run well or just being run. Four things a buyer will check:
- Hygiene production as a percentage of total practice production. Target: 25 to 35 percent.
- Hygienist production per hour. Target: $180 to $240 depending on region and mix.
- Reappointment rate. Target: 90 percent plus at the point the patient leaves the chair.
- Active patient count (seen in last 18 months) trending up or flat, not down.
Doctor compensation normalization
A standard diligence adjustment: the buyer will recalculate your EBITDA assuming a market-rate doctor compensation for the work you personally produced. If you are taking out 45 percent of collections as doctor comp and the market rate for your production type is 32 percent, the difference flows through to EBITDA, which flows through to price.
This adjustment is the single biggest surprise for owners who have not pre-modeled it. A practice that looks like $600K EBITDA to you might be $460K EBITDA to a buyer, not because of anything you did wrong, but because the accounting conventions are different.
Real estate
If you own the building, you have an asset-valuation question separate from the practice sale. Most DSOs will pay a long-term triple-net lease that clears you a market cap rate on the real estate, effectively letting you separate the two assets. The lease terms on a dental medical office building run 10 to 15 years with options, triple-net structure, rent escalations of 2 to 3 percent annually.
If you lease from a third party, the lease becomes a deal term. Minimum remaining term buyers want: 7 to 10 years with renewal options. Shorter than that means renegotiation risk, and the buyer will either price that risk in or require landlord participation in the deal.
What changed since 2023
Three structural shifts that make 2026 deals look different on paper than 2022 deals:
Debt cost to the buyer
DSO cost of capital roughly doubled from 2022 to 2024 and has only partially recovered. Buyers now solve for their own debt service first, which creates a ceiling on what they can pay. Multiples compressed most at the top of the range.
Cash-at-close percentage
2022 deals averaged ~80 percent cash at close and ~20 percent deferred (rollover plus earnout plus holdback). 2026 deals average closer to 65/35. The headline number did not change; the risk shifted to the seller.
Diligence intensity
Quality-of-earnings reviews are longer, deeper, and more confrontational. 60 to 90 days of process, with real operational disruption. Buyers push back on EBITDA adjustments that would not have been challenged three years ago. The net effect is that practices that have not run a pre-market QoE are walking into diligence unprepared.
Valuation Snapshot
Request a practice valuation review.
Send the basic numbers and I will identify the valuation questions worth answering before you speak with a DSO, broker, or buyer.